A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.

Item
http://www.wikidata.org/entity/Q33375584
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveSevere reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling.Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.The role of proteasome inhibition in nonsmall cell lung cancerMass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidancePlatinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.Positioning of proteasome inhibitors in therapy of solid malignancies.
P2860

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.

Item
http://www.wikidata.org/entity/Q33375584
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@ast
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@en
type
label
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@ast
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@en
prefLabel
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@ast
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P356
P1433
P1476
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-07-0061
P407
P433
P478
P50
P577
P5875
P698